First Tracks Biotherapeutics, Inc. TRAX
—
34.42
(1.41)
(3.94%)
as of 25 Sep
- Market cap
- $1.3B
- P/E
- —
Follow TRAX
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+1 more TTM period Free account |
— | — | — | 0.00% | |
| — | — | — | (189.47%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (14,855.88%) | |
Return on Tangible Assets |
— | 0.00% | 0.00% | (104.29%) | |
Free Cash Flow per Share |
0.00 | — | — | (4.23) | |
Free Cash Flow |
— | — | — | (148.24) | |
Capital Expenditures |
— | — | — | (0.12) | |
Piotroski F-Score |
— | — | — | 1.00 | |
| Other line items | |||||
Cash ROIC |
0.00% | 0.00% | 0.00% | (43.98%) | |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | |
Tax Rate |
— | — | — | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 0.00% | |
Share Based Compensation of Revenue |
— | — | — | 0.00% | |
Interest Coverage |
— | — | — | 0.00 | |
Operating CF/Net income |
— | — | — | 0.85 | |
Depreciation/Fixed assets |
— | 0.00 | 0.00 | (1.48) | |
Capex/Depreciation |
— | — | — | 0.07 | |
Revenue per Share |
0.00 | — | — | 0.00 | |
Operating CF per Share |
0.00 | — | — | (4.23) | |
Capex per Share |
0.00 | — | — | 0.00 | |
Capex to Sales |
— | — | — | 0.00 | |
Net Profit Margin |
— | — | — | 0.00% |
Columns are period end dates